Northwest Biotherapeutics, Inc. (OTCPK: NWBO)
Health Care · Biotechnology · US
$0.15
-3.94% today · -39.1% 1Y
Northwest Biotherapeutics, Inc. (OTCPK: NWBO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $262.16M and employs 105 people.
Over the last twelve months the share price has lost 39.1%, trading between 0.14 and 0.34.
Tweenvest scores Northwest Biotherapeutics, Inc. across four factors: quality 8/100, value 55/100, growth 0/100. Its strongest factor is value.
NWBO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $262.16M
- Revenue (TTM)
- $2.17M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- -0.61
- 52-week high
- $0.34
- 52-week low
- $0.14
- Avg volume (3M)
- —
- Shares outstanding
- 1.71B
- Employees
- 105
- Next earnings
- —
About Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
- ISIN
- US66737P6007
- Founded
- 1996
- Listed since
- Dec 14, 2001
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AC Immune SANasdaqGM: ACIU | $270.94M | $2.55 | -6.42% |
| TriSalus Life Sciences, Inc.NasdaqGM: TLSI | $266.00M | $4.13 | -4.40% |
| Immuneering CorporationNasdaqGM: IMRX | $263.32M | $3.74 | -8.11% |
| AIM Vaccine Co., Ltd.SEHK: 6660 | $262.60M | HK$1.68 | -0.88% |
| Racura Oncology LtdASX: RAC | $261.64M | AU$1.92 | -6.34% |
| Vicore Pharma Holding AB (publ)OM: VICO | $261.45M | Skr9.32 | -2.92% |
| Anika Therapeutics, Inc.NasdaqGS: ANIK | $261.37M | $19.23 | -1.54% |
| Bicycle Therapeutics plcNasdaqGS: BCYC | $261.07M | $3.81 | +2.14% |
Figures last refreshed Oct 4, 2026.